Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

☰

How Much Cash Kite Pharma's Execs Made From Its $12 Billion Gilead Deal

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-investor.jpg" NAME"How Much Cash Kite Pharma's Execs Made From Its $12 Billion Gilead Deal" ALT"How Much Cash Kite Pharma's Execs Made From Its $12 Billion Gilead Deal"September 29, 2017By…

Continue ReadingHow Much Cash Kite Pharma's Execs Made From Its $12 Billion Gilead Deal

As Its R&D Boss 'Retires,' Eli Lilly CEO Taps an Entirely New C-Suite for 2018

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-eli-lilly2.jpg" NAME"As Its R&D Boss 'Retires,' Eli Lilly CEO Taps an Entirely New C-Suite for 2018" ALT"As Its R&D Boss 'Retires,' Eli Lilly CEO Taps an Entirely New C-Suite…

Continue ReadingAs Its R&D Boss 'Retires,' Eli Lilly CEO Taps an Entirely New C-Suite for 2018